Search

Author/Creator Sung, Max

1. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. Issue 6 (16th June 2022)

Authors:
Marinelli, Brett; Kim, Edward; D'Alessio, Antonio; Cedillo, Mario; Sinha, Ishan; Debnath, Neha; Kudo, Masatoshi; Nishida, Naoshi; Saeed, Anwaar; Hildebrand, Hannah; Kaseb, Ahmed O; Abugabal, Yehia I; Pillai, Anjana; Huang, Yi-Hsiang; Khan, Uqba; Muzaffar, Mahvish; Naqash, Abdul Rafeh; Patel, Rahu...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 6(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. (August 2021)

Authors:
Vogel, Arndt; Qin, Shukui; Kudo, Masatoshi; Su, Yun; Hudgens, Stacie; Yamashita, Tatsuya; Yoon, Jung-Hwan; Fartoux, Laetitia; Simon, Krzysztof; López, Carlos; Sung, Max; Mody, Kalgi; Ohtsuka, Tatsuroh; Tamai, Toshiyuki; Bennett, Lee; Meier, Genevieve; Breder, Valery
Journal:
Lancet gastroenterology and hepatology
Issue:
Volume 6:Number 8(2021)
Page Start:
649
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗